Rapid detection of AML1 associated fusion genes in patients with adult acute myeloid leukemia and its clinical significance.
10.7534/j.issn.1009-2137.2013.04.002
- Author:
Meng-Meng JIANG
1
,
2
;
Li GAO
;
Yu JING
;
Yi DING
;
Yuan-Yuan XU
;
Min-Hang ZHOU
;
Chao MA
;
Nan WANG
;
Wei WANG
;
Xiao-Ping HAN
;
Hong-Hua LI
;
Quan-Shun WANG
;
Li-Li WANG
;
Li YU
Author Information
1. Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China
2. Medical School, Nankai University, Tianjin 300071, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Aged;
Aged, 80 and over;
Core Binding Factor Alpha 2 Subunit;
genetics;
Female;
Humans;
Leukemia, Myeloid, Acute;
diagnosis;
drug therapy;
genetics;
Male;
Middle Aged;
Oncogene Proteins, Fusion;
genetics;
Prognosis;
Remission Induction;
Reverse Transcriptase Polymerase Chain Reaction;
Young Adult
- From:
Journal of Experimental Hematology
2013;21(4):821-829
- CountryChina
- Language:English
-
Abstract:
This study was aimed to detect the expression of AML1 fusion genes in the patients with adult acute myeloid leukemia (AML) and further to investigate their association with the progression and prognosis of AML. Bone marrow samples were collected from 168 patients with de novo adult AML, and the expression of AML1 ETO, AML1-EVI1, AML1-MDS1, AML1-MTG16, AML1-PRDM16, AML1-LRP16, AML1-CLCA2 and AML1-PRDX4 was analyzed by a novel multiplex nested RT-PCR. Positive samples and minimal residual disease were further examined by real-time fluorescent quantitative PCR. The results showed that the AML1 fusion genes were found in 10.7% (18/168) patients. Among them, AML1-ETO in 12 (7.1%) cases were detected, AML1-EVI1 in 2 cases (1.2%), and AML1-MDS1, AML1-MTG16, AML1-PRDM16, and AML1-CLCA2 in 1 case (0.6%) each were detected. Among the patients with AML1-ETO, 10 patients (10/12, 83.33%) achieved complete remission (CR) after one cycle of chemotherapy, while 2 patients achieved CR after 2 cycles of chemotherapy. The 2 patients with AML1-EVI1 failed to achieve CR after one cycle of chemotherapy. Patients with AML1-MDS1, AML1-MTG16, AML1-PRDM16, or AML1-CACL2 did not achieve CR after one cycle of chemotherapy. It is concluded that AML1 fusion genes are more frequent and can provide the molecular markers for diagnostics and prognosis evaluation of AML and for monitoring MRD.
